Navigation Links
Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
Date:7/7/2011

PARSIPPANY, N.J., July 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the Southern District of Florida's February 2011 decision that Watson's generic versions of Mucinex(R) (Guaifenesin), Mucinex(R) D (Pseudoephedrine/Guaifenesin), and Mucinex(R) DM (Dextromethorphan HBr/ Guaifenesin) Extended-Release products do not infringe U.S. Patent No. 6,372,252.

The Company said it is continuing to seek final FDA approval of the products.

In 2009, Reckitt Benckiser Inc. sued Watson Laboratories, Inc. – Florida for patent infringement related to Watson's filing of three Abbreviated New Drug Applications for generic versions of Reckitt's Mucinex(R) line of products. The Mucinex(R) products had total U.S. sales of approximately $500 million for the twelve months ending December 31, 2010, according to IRI and are indicated to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets. For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Mucinex(R) is a registered trademark of Reckitt Benckiser LLC.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... analytics to its patient care management module. Using this new feature, sleep physicians ... has been initiated on continuous positive airway pressure (CPAP), oral, or other forms ...
(Date:4/25/2017)... ... ... There is no better place in South Florida to undergo two common heart ... of Consumer Reports focused on heart health. , The magazine gave Memorial ... bypass and aortic valve replacement procedures. , Consumer Reports rated Memorial’s Cardiac ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., ... of its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), ... and effective management of complex spine deformity cases, particularly in children. , GSO’s ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The Santana Telehealth ... ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on April 23 ... Project for using telemedicine to improve the lives of the poor and underserved in ...
Breaking Medicine News(10 mins):